Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PTPRC | P08575 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11120257 | 0.80 | CYP1A2 (0.35) | — | |
| SCHEMBL8058639 | 0.75 | CYP2A6 (0.36) | MAPTLMNAKDM4EALDH1A1POLB | |
| SCHEMBL8776016 | 0.75 | CYP2A6 (0.36) | MAPTLMNAKDM4EALDH1A1POLB | |
| SCHEMBL205284 | 0.75 | — | — | |
| SCHEMBL22635713 | 0.73 | GAA (0.33) | MAPTGAA | |
| SCHEMBL22635712 | 0.73 | GAA (0.33) | MAPTGAA | |
| SCHEMBL3767165 | 0.71 | MAPT (0.53) | MAPTGAALMNAKDM4EMEN1 | |
| SCHEMBL33554 | 0.71 | — | — | |
| SCHEMBL29375766 | 0.71 | MAPT (0.53) | MAPTGAALMNAKDM4EMEN1 | |
| SCHEMBL29398195 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371367-A1 | TRIARYLMETHANE COMPOUNDS | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2021-12-02 | — | — | US | claimed |
| EP-3749631-A1 | TRIARYLMETHANE COMPOUNDS | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2020-12-16 | — | — | EP | claimed |
| WO-2019154727-A1 | TRIARYLMETHANE COMPOUNDS | REUTER CHEMISCHE APPARATEBAU KG (DE) | 2019-08-15 | — | — | WO | claimed |
| WO-2019154730-A1 | TRIARYLMETHANE COMPOUNDS | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2019-08-15 | — | — | WO | claimed |
| US-20140031371-A1 | POLY AROMATIC SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2014-01-30 | — | — | US | claimed |
| WO-2013026455-A1 | PERMANENTLY POSITIVELY CHARGED ANTIDEPRESSANTS | AARHUS UNIVERSITET (DK) | 2013-02-28 | — | — | WO | claimed |
| US-8124607-B2 | Poly aromatic pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2012-02-28 | — | — | US | claimed |
| US-8034941-B2 | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-11 | — | — | US | claimed |
| EP-2257296-A1 | POLY AROMATIC SODIUM CHANNEL BLOCKERS | Parion Sciences, Inc. (US) | 2010-12-08 | — | — | EP | claimed |
| EP-2228375-A1 | New xanthin derivatives, their production and utilisation as medicine | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2010-09-15 | — | — | EP | claimed |
| EP-1055672-A1 | 1,4-DIHYDROPYRIDINE DERIVATIVES | Nikken Chemicals Company, Limited (JP) | 2000-11-29 | — | — | EP | claimed |
| US-6069224-A | CHARGE TRANSPORTING PROPERTIES, PHOTOSENSITIVITY | RICOH COMPANY, LTD. (JP) | 2000-05-30 | — | — | US | claimed |
| US-5410046-A | Selective muscarinic receptor antagonists | PFIZER INC. (US) | 1995-04-25 | — | — | US | claimed |
| EP-0511270-A1 | NEW THIAZOLE DERIVATIVES | CEDONA PHARMACEUTICALS B.V. (NL) | 1992-11-04 | — | — | EP | claimed |
| US-5089505-A | Anticholinergic agents | PFIZER INC. (US) | 1992-02-18 | — | — | US | claimed |
| WO-1991010657-A1 | NEW THIAZOLE DERIVATIVES | CEDONA PHARMACEUTICALS B.V. (NL) | 1991-07-25 | — | — | WO | claimed |
| US-5024912-A | 5H-dibenzo(A,D) cycloheptanylidene derivative and 5H-dibenzo (A,D) cycloheptenylidene derivative, and electrophotographic photosensitive member using the same | CANON KABUSHIKI KAISHA (JP) | 1991-06-18 | — | — | US | claimed |
| US-4877779-A | CALCIUM CHANNEL BLOCKERS; TREATMENT OF IRRITABLE BOWEL SYNDROME | MARION LABORATORIES, INC. (US) | 1989-10-31 | — | — | US | claimed |
| EP-0109299-A2 | 1,1-Disubstituted-2-heterocyclic ethanol derivatives | ELI LILLY AND COMPANY (US) | 1984-05-23 | — | — | EP | claimed |
| US-4116665-A | Method of regulating the growth of aquatic weeds with pyridine derivatives | ELI LILLY AND COMPANY (US) | 1978-09-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371367-A1 | TRIARYLMETHANE COMPOUNDS | CBR3, HAX1, HRH3 | MAPT 4486/4885GAA 2963/4885LMNA 1611/4885 |
| US-20140031371-A1 | POLY AROMATIC SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCNN1B | MAPT 1110/4885GAA 1987/4885LMNA 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.